Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

Sponsor
Zhejiang University
Study ID
NCT07199855
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • B-Cell Acute Lymphoblastic Leukemia, Adult

Eligibility Criteria

Sex
ALL
Age
14 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a single-center, single-arm, prospective clinical trial evaluating the efficacy and safety of blinatumomab combined with venetoclax as maintenance therapy for high-risk Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation .

Key Dates

Start date
Jun 1, 2025
Status verified
Jul 2025
Primary completion
Jun 1, 2027
Completion
Jul 1, 2029

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: blinatumomab combined with venetoclax as maintenance therapy
    blinatumomab combined with venetoclax as maintenance therapy for high-risk Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation

Primary Outcome Measure

the 2-year progression-free survival (PFS) rate post-transplantation [ Time Frame: the 2-year progression-free survival (PFS) rate post-transplantation ]

Related Studies